Tang Youyong, Zhang Zhijun, Song Xingguo, Yu Miao, Niu Limin, Zhao Yajing, Wang Li, Song Xianrang, Xie Li
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Department of Clinical Laboratory, Taian City Central Hospital, Taian, China.
J Oncol. 2020 Dec 1;2020:6691211. doi: 10.1155/2020/6691211. eCollection 2020.
Evidence has suggested the functional role of exosomal miRNAs in cancer diagnosis. This study aimed to determine whether the serum exosomal biomarkers can improve the diagnosis of patients with non-small-cell lung cancer (NSCLC).
The exosomes were extracted from the serum of NSCLC patients ( = 235) and healthy donors ( = 231) using ultracentrifugation and then were evaluated by using transmission electron microscopy, qNano, and western blotting. The serum exosomal miRNA expression was validated using qPCR.
Exosomal miR-620 was significantly reduced in NSCLC and early-stage NSCLC patients ( < 0.0001) when compared to that of healthy controls, with an area under the curve (AUC) of 0.728 and 0.707, respectively. Exosomal miR-620 expression showed an association with drinking (=0.008) and distant metastasis (=0.037). Additionally, the downregulated exosomal miR-620 showed association with chemotherapeutic effect (=0.044).
These findings suggest the serum exosomal miR-620 as a promising diagnostic and prognostic noninvasive biomarker in NSCLC patients.
有证据表明外泌体微小RNA在癌症诊断中发挥功能作用。本研究旨在确定血清外泌体生物标志物是否能改善非小细胞肺癌（NSCLC）患者的诊断。
采用超速离心法从NSCLC患者（n = 235）和健康供体（n = 231）的血清中提取外泌体，然后通过透射电子显微镜、qNano和蛋白质印迹法进行评估。使用qPCR验证血清外泌体微小RNA的表达。
与健康对照相比，NSCLC患者和早期NSCLC患者的外泌体miR - 620显著降低（P < 0.0001），曲线下面积（AUC）分别为0.728和0.707。外泌体miR - 620表达与饮酒（P = 0.008）和远处转移（P = 0.037）相关。此外，外泌体miR - 620下调与化疗效果相关（P = 0.044）。
这些发现表明血清外泌体miR - 620是NSCLC患者一种有前景的诊断和预后非侵入性生物标志物。
